EVM
AGIO icon

Eaton Vance Management’s Agios Pharmaceuticals AGIO Stock Holding History

Eaton Vance Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.94M Sell
68,447
-6,525
-9% -$175K ﹤0.01% 1066
2022
Q2 		$1.66M Sell
74,972
-1
-0% -$23 ﹤0.01% 1135
2022
Q1 		$2.18M Buy
74,973
+1
+0% +$31 ﹤0.01% 1152
2021
Q4 		$2.46M Hold
74,972
– – ﹤0.01% 978
2021
Q3 		$3.46M Hold
74,972
– – ﹤0.01% 810
2021
Q2 		$4.13M Sell
74,972
-627
-0.8% -$35.1K 0.01% 828
2021
Q1 		$3.9M Buy
75,599
+507
+0.7% +$25.1K 0.01% 808
2020
Q4 		$3.25M Hold
75,092
– – 0.01% 819
2020
Q3 		$2.63M Hold
75,092
– – ﹤0.01% 769
2020
Q2 		$4.02M Sell
75,092
-25
-0% -$1.16K 0.01% 654
2020
Q1 		$2.67M Hold
75,117
– – 0.01% 695
2019
Q4 		$3.59M Buy
75,117
+76
+0.1% +$2.87K 0.01% 702
2019
Q3 		$2.43M Sell
75,041
-58,879
-44% -$2.44M 0.01% 768
2019
Q2 		$6.68M Sell
133,920
-33,550
-20% -$1.79M 0.01% 524
2019
Q1 		$11.3M Buy
167,470
+50,738
+43% +$2.96M 0.03% 390
2018
Q4 		$5.38M Buy
116,732
+10,484
+10% +$647K 0.01% 496
2018
Q3 		$8.19M Hold
106,248
– – 0.02% 451
2018
Q2 		$8.95M Sell
106,248
-66,064
-38% -$5.76M 0.02% 421
2018
Q1 		$14.1M Buy
172,312
+73,691
+75% +$5.7M 0.02% 444
2017
Q4 		$5.64M Buy
98,621
+43,741
+80% +$2.75M 0.01% 495
2017
Q3 		$3.66M Hold
54,880
– – 0.01% 558
2017
Q2 		$2.82M Hold
54,880
– – 0.01% 602
2017
Q1 		$3.21M Hold
54,880
– – 0.01% 548
2016
Q4 		$2.29M Hold
54,880
– – 0.01% 578
2016
Q3 		$2.9M Hold
54,880
– – 0.01% 518
2016
Q2 		$2.3M Hold
54,880
– – 0.01% 539
2016
Q1 		$2.23M Hold
54,880
– – 0.01% 533
2015
Q4 		$3.56M Hold
54,880
– – 0.01% 462
2015
Q3 		$3.87M Buy
+54,880
New +$5.36M 0.01% 440

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Eaton Vance Management's AGIO Position: Q3 2022 in Review

Eaton Vance Management reduced its Agios Pharmaceuticals (AGIO) stake by 8.7% in Q3 2022, selling an estimated $175K and leaving 68,447 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1066.

Eaton Vance Management first reported a position in AGIO in Q3 2015 and has held it in 29 quarters since. The position peaked at $14.1M in Q1 2018. 169 funds tracked by Wall St. Rank hold AGIO as of Q3 2022.

  • Eaton Vance Management held 68,447 shares of Agios Pharmaceuticals worth $1.94M as of Q3 2022.
  • Eaton Vance Management sold 6,525 Agios Pharmaceuticals shares in Q3 2022, an estimated $175K.
  • Agios Pharmaceuticals made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #1066 holding.
  • Eaton Vance Management first reported a position in Agios Pharmaceuticals in Q3 2015 and has held it in 29 quarters since.
  • Eaton Vance Management's Agios Pharmaceuticals position peaked at $14.1M in Q1 2018.
  • 169 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.